Compositions and methods for modified dendrimer nanoparticle delivery
US12419940B2 · kind B2 · utility
0Cited by
1References
23Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 10, 2021 |
| Grant date | Sep 23, 2025 |
| Priority date | — |
| Expiry date | Dec 18, 2041 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods for modified dendrimer nanoparticle (“MDNP”) delivery of therapeutic, prophylactic and/or diagnostic agent such as large repRNA molecules to the cells of a subject have been developed. MDNPs efficiently drive proliferation of antigen-specific T cells against intracellular antigen, and potentiate antigen-specific antibody responses. MDNPs can be multiplexed to deliver two or more different repRNAs to modify expression kinetics of encoded antigens and to simultaneous deliver repRNAs and mRNAs including the same UTR elements that promote expression of encoded antigens.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.